- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
David Fabrizio on the Use of Genomic Profiling to Predict Patient Response to Cancer Treatment
Genomic-based solutions can help identify which cancer patients will respond better to treatment based on biomarkers, said David Fabrizio of Foundation Medicine, Inc.
Genomic-based solutions can help identify which cancer patients will respond better to treatment based on biomarkers, said David Fabrizio of Foundation Medicine, Inc.
Transcript (slightly modified)
Do you think the immunotherapy field needs a different approach to predict patient response to treatment?
Yeah, absolutely. I think right now IHC [immunohistochemistry] is the current method, and I spoke to some of the limitations, I think there are significant limitations to IHC. I think we need genomic-based solutions, quantitative solutions that can be universally adopted. So something like tumor mutational burden [TMB], which can be measured through comprehensive genomic profiling, is a solution.
And we know this because we’ve looked at the utility over more than 500 patients right now, in disease areas that include non-small cell lung cancer, bladder cancer, and metastatic melanoma, and we’ve published these results showing that you can identify biomarker-positive patients that in some cases lived 3 times longer than the negative group without their disease getting any worse, and that’s in lung cancer. In the bladder and melanoma studies, the biomarker-positive groups for TMB weren’t reached, the median survival wasn’t reached, compared to the ones who were negative. So it does have resounding clinical utility, and I think we’re going to start to see that expand to other indications.
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
